BTB Korea한국비티비

BTB Korea is loss-making on a trailing basis, with its share price up sharply over three months but down about 50% over one year.

BTB Korea runs a medical beauty device business and a bioscience reagent distribution business. Trailing twelve-month figures to H1 2026 show revenue of about ₩26.9B, an operating loss of about ₩5.5B and negative free cash flow of about ₩5.8B. The shares closed at ₩2,640 on 2026-10-30, a market value of about ₩34.5B.

What stands out

• Revenue fell from about ₩32.0B in 2025 to a trailing ₩26.9B by H1 2026, and the operating margin is -20.3%.
• The company has posted operating losses in every year from 2021 to the trailing period, with 2024 the only year near break-even at a 3.3% operating margin.
• Liabilities are about 101% of equity, with ₩13.0B of borrowings against ₩2.8B of cash.
• The share price is up 57.3% over one month and 52.6% over three months, but down 49.9% over one year and well below its 52-week high of about ₩5,765.
• Foreign ownership fell from 0.1% to 0% over the last 60 days, and the data shows no short-selling balance.

What to watch

• The next quarterly or half-year filings, to see whether losses narrow from the trailing figures.
• Filings showing 5%+ holding and insider shareholding changes, which were reported in July 2026.
• Debt levels against cash, since borrowings of ₩13.0B exceed cash of ₩2.8B and free cash flow is negative; the data does not include a funding plan.